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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of conservative interventions for urinary or faecal incontinence (or both) in adults with multiple sclerosis, compared
to no treatment, sham and usual care, any other active treatment, or another conservative treatment.
To critically appraise and summarise the current evidence on resource use, costs and cost effectiveness of conservative interventions for
adults with urinary or faecal incontinence (or both) and MS.
We will make the following comparisons.
• Conservative treatment versus no treatment
• Conservative treatment versus sham treatment
• Conservative treatment versus usual care
• Conservative treatment versus pharmacological treatment
• Conservative treatment versus surgical treatment
• Conservative treatment versus any other conservative treatment
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B A C K G R O U N D
Description of the condition
Diminished control of bladder and bowel function is prevalent
among individuals with multiple sclerosis (MS), although accu-
rate estimates of incontinence are hampered by a lack of standard-
ised definitions in epidemiology studies (Apostolidis 2017; Krogh
2009; Milsom 2017). Urinary incontinence (UI), defined as the
“complaint of any involuntary loss of urine”(Abrams 2017), is re-
ported to affect between 19% and 80% of individuals with MS,
according to the definition used (Apostolidis 2017; Forbes 2006).
Less is known about faecal incontinence (FI), defined broadly as
“any involuntary loss of faecal material”(Abrams 2017), with a fur-
ther definition of anal incontinence (AI) that includes the invol-
untary passing of flatus. Epidemiology studies to date have lacked
specificity to draw robust conclusions, however, the more conser-
vative studies estimate that up to 30% of the MS population is af-
fected by FI at least monthly (Hennessey 1999; Koldewijn 1995).
Reported prevalence is higher in more recent studies: 50% and
over (DasGupta 2003; Norton 2010). Duration of disease and
the severity of deficiencies caused by MS are important factors in
the occurrence of bladder dysfunction (de Sèze 2007), while only
the latter has been reported as a correlate with digestive disorders
(Munteis 2008). UI and FI often occur together - which is under-
standable given the shared musculature, shared innervation, and
the propensity of MS to cause spinal cord dysfunction - however
they are often treated and evaluated separately. Thus less is known
about the prevalence, treatment and outcomes for UI and FI in
combination (Donzé 2009). The additional consideration of re-
duced mobility that may occur with MS can cause further diffi-
culties with the occurrence of incontinence and such associated
factors should not be overlooked.
There are few studies which evaluate the impact of incontinence
on the quality of life of people with MS, but these studies have
reported similar issues to those conducted in a non-MS popu-
lation. Factors reported to be associated with incontincence and
MS are shame (Koch 2001), embarrassment (Wollin 2005), and
interference with sex life (Borello-France 2004; Hennessey 1999).
More generically, effects such as social isolation, reduced self-es-
teem, restriction of activities and toilet mapping are common,
with individuals’ lives being controlled by their bladder and bowel
(Cotterill 2008; Donovan 2005; Norton 2010). Incontinence has
been identified as having a significant impact on emotional health,
ability to perform household chores, and physical recreation, all
of which are central to functioning in society (Khan 2009; Wollin
2005).
Studies to evaluate the costs of incontinence often focus on the ex-
penditure associated with the use of continence pads, other prod-
ucts, laundry and dry cleaning (Fader 2008). Studies on costs have
largely focused on females in the general population, rather than
those with MS specifically. Findings suggest that costs for incon-
tinence management increase with leakage severity and are higher
for mixed urinary incontinence by comparison with stress urinary
incontinence (SUI) (Subak 2007). Substantial economic burden
has also been associated with urinary incontinence due to neu-
rogenic detrusor overactivity (Tapia 2013). Effective conservative
treatment intervention has been associated with decreased costs of
incontinence management at the personal level in a trial of weight
loss for women with urinary incontinence (Subak 2012). With re-
gard to faecal incontinence, a similar association between severity
of symptoms and personal costs was reported in a study of men
and women presenting to a tertiary referral centre. When costs for
medical care were included the association with severity was not
evident (Parkin 2011).
The lower urinary tract (LUT) and the anorectum (AR) are inter-
related structures under neural control that require reservoir func-
tion and effective closure of the urethral and anal sphincters to
achieve continence. The diffuse neurodegeneration and particu-
larly involvement of the spinal cord, such as found in MS, affect
function of the LUT and AR (Apostolidis 2017).
Lower urinary tract dysfunction (LUTD) occurs in 50% to 92%
of patients withMS (DasGupta 2002; Giannantoni 1999; Hinson
1996; Khalaf 2015; Litwiller 1999). The most common urody-
namic findings among individuals referred for urodynamic evalu-
ation are detrusor overactivity (involuntary contraction of the de-
trusor muscle; mean 65%), detrusor sphincter dyssynergia (unco-
ordinated activity between the detrusor and urethral sphincter;
mean 35%) and detrusor underactivity (weak contraction of the
detrusor; mean 25%) (de Sèze 2007). UI can be associated with
these conditions or occur in isolation, and presents in different
forms as defined below (Abrams 2017).
• Stress urinary incontinence: the complaint of involuntary
leakage on effort or exertion, or on sneezing or coughing.
• Urodynamic stress incontinence: a urodynamic
observation characterised by the involuntary leakage of urine
during increased abdominal pressure, in the absence of a detrusor
contraction.
• Urgency urinary incontinence: the complaint of
involuntary leakage accompanied by or immediately preceded by
urgency.
• Detrusor overactivity: a urodynamic observation
characterised by involuntary detrusor contractions during the
filling phase, which may be spontaneous or provoked. This is
further defined as neurogenic detrusor overactivity if the
overactivity is due to a relevant neurological condition.
• Mixed urinary incontinence: the complaint of involuntary
leakage associated with urgency and also with effort, exertion,
sneezing and coughing.
Bowel dysfunction is less studied, but similar mechanisms for this
type of incontinence exist. Interruption of the afferent nerves may
alter awareness of the need to open the bowels, and compromise of
the efferent nervesmay affect innervation of the intestines and vol-
untary control of the pelvic floor, in addition to reduced anorectal
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sensation. About one-third of individuals withMS experience con-
stipation and one-quarter are incontinent of faeces at least once per
week (Bakke 1996; Hinds 1990). The main distinction between
descriptions of incontinence regarding the bowel is the inclusion
or exclusion of flatus as defined below (Abrams 2017).
• Anal incontinence (AI): any involuntary loss of faecal
material, flatus, or mucus (alone or in combination).
• Faecal incontinence: any involuntary loss of faecal
material.
• Flatus incontinence: any involuntary loss of gas (flatus).
For the purposes of this review, we will use AI unless the exclusion
of flatus incontinence is specified.
It is noted that there is currently no accepted definition of mixed
urinary and anal or faecal incontinence. In order to include studies
that have studied this population, for the purposes of this review
we propose the definition below, as a combination of the published
definitions.
• Mixed urinary and faecal incontinence: the complaint of
any involuntary loss of urine and involuntary loss of faecal
material.
• Mixed urinary and anal incontinence: as above with the
addition of involuntary loss of flatus.
Description of the intervention
Treatments for UI and AI - both associated with MS and in the
wider population - include conservative treatments (physical ther-
apies, lifestyle and behavioural adaptations and symptommanage-
ment), drug therapy or surgical treatments (Cotterill 2018; Drake
2016). The focus of this review is conservative treatments, which
excludes pharmacological and surgical interventions. We will in-
clude the conservative interventions outlined in the sixth Inter-
national Consultation on Incontinence (Abrams 2017). Physical
therapies include pelvic floor muscle training (PFMT), weighted
vaginal cones, electrical stimulation, posterior tibial nerve stimu-
lation (PTNS), magnetic stimulation and biofeedback. Lifestyle
and behavioural adaptations include education regarding diet and
behaviour choices and scheduled voiding and bowel management
regimens. Symptom management includes rectal irrigation and
intermittent catheter use.
How the intervention might work
Conservative management plays an important role in the treat-
ment of UI and AI as these interventions are the recommended
first line of treatment and offer alternative modalities to pharma-
cological and surgical interventions. Each strategy is detailed be-
low to explore the mechanism of action to improve incontinence
symptoms.
Pelvic floor muscle training (PFMT)
PFMT was popularised by Arnold Kegel (Kegel 1948) for the
management of UI and is defined as repetitive selective voluntary
contraction and relaxation of specific pelvic floor muscles (Abrams
2002). Although initially used for the management of UI, in par-
ticular SUI, as the integrity of the pelvic floor appears key to the
entire continence mechanism (Salvatore 2017), its potential ben-
efits have been proposed for other types of UI and AI (Bliss 2017;
Dumoulin 2017). The aims of PFMT are to promote increased
strength in the pelvic floor to provide more automatic protection
and more effective voluntary recruitment of these muscles under
times of increased abdominal pressure (Bø 2004). Patients are in-
structed to contract the pelvic floormuscles, including the external
anal sphincter and puborectalis, while keeping the abdominal wall
muscles relaxed, repeating these exercises several times per day.
Weighted vaginal cones
For use in women only, weighted vaginal cones were originally
used to test pelvic floor muscle function and are anticipated to
improve continence through strengthening, as with PFMT. Cones
vary inweight and size and are inserted into the vaginawith the aim
of retaining the cone over increasing periods of time and activity,
thereby increasing the strength of the muscles required to retain
the cone (Peattie 1988; Plevnik 1985).
Electrical stimulation
Electrical stimulation is the application of electrodes on the per-
ineum or probes in the vagina or anal canal to apply mechani-
cal stimulation to the pelvic floor muscles. Underpinning theories
suggest themechanical contraction of themuscles enables patients
to identify the relevantmuscles in order to support and implement
their own contractions, and that the additional stimulation may
promote synaptic growth or the size of receptive fields for these
nerves in the brain (Hosker 2007). In addition, there is a suggested
effect on sensation and the perception of filling by stimulating
awareness (Berghmans 2013).
Posterior tibial nerve stimulation (PTNS)
PTNS involves the stimulation of the tibial nerves in order to
modify the action of the sacral nerve plexus, which is responsi-
ble for regulation of bladder and bowel function. A mild electric
current is delivered by a needle or surface electrode to the tibial
nerve above the ankle, which is carried to the sacral nerves. The
mechanism underlying the effect is poorly understood but is de-
scribed as the modulation and stimulation of efferent and afferent
nerves, and associations with increased rectal capacity and lower
sensitivity to distension have been reported (Marti 2017).
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Magnetic stimulation
Magnetic stimulation is a non-invasive method of stimulating the
central and peripheral nervous systemswithout the need for probes
or electrodes (Galloway 1999; Goldberg 2000). Amagnetic field is
generated and directed toward the pelvic floor muscles and sacral
nerve roots, allowing all tissues of the perineum to be targeted.
The mechanism of action is not fully understood but magnetic
stimulation is thought to cause sphincter contraction, act as passive
pelvic floor muscle exercise, increase urethral closure pressures and
affect neural activity to reduce detrusor overactivity (But 2003;
Bycroft 2004; Kralj 1999; Lindström 1983).
Biofeedback
Biofeedback is used in addition to the interventions described
above and uses the principle of conveying information about a
normally unconscious physiological process to the patient or ther-
apist as a visual, auditory or tactile signal. Communicating this
information can be used to teach patients to recognise and increase
or decrease their voluntary muscle activity (Doggweiler-Wiygul
2002), and aims to improve the accuracy, effectiveness, or duration
of pelvic floor muscle contractions. In addition, sensory training
can be incorporated into biofeedback training protocols to im-
prove recognition of sensation associated with stool moving into
the rectum which can be reduced with neurological disorders such
as MS (Bliss 2017). A balloon-tipped catheter is inserted into the
rectum and inflated with varying volumes of air to help the patient
recognise varying distensions and perform balloon expulsion in
order to better co-ordinate pelvic floor muscle activity.
Lifestyle interventions
A number of lifestyle factors may have an influence on the symp-
toms of UI and AI, for example: excessive weight, lack of physical
activity, smoking, diet, caffeine, fluid and dietary intake (includ-
ing content and patterns), constipation, medication side effects,
toilet facilities and access, and patient or carer education. Often
patients have a lack of understanding of the effect of these factors
on bladder and bowel habits and therefore education and advice,
in addition to specific supportive interventions such as peer sup-
port and motivational strategies, are crucial to addressing these
modifiable factors. Reducing the effects or improving strategies
associated with these factors is proposed to reduce the symptoms
of incontinence by limiting the irritative or physical effects on the
bladder and bowel, and increasing knowledge in order to optimise
healthy habits (Dumoulin 2017).
Scheduled voiding and bowel management regimens
These are broad terms to describe toileting interventions intended
to improve bladder and bowel patterns in order to avoid ormanage
symptoms. With regard to UI, these interventions can be divided
into three main strategies, as follows.
• Bladder training: a scheduled voiding regimen with
progressively increasing voiding intervals, which aims to correct
frequent urination habits.
• Timed voiding: a fixed voiding schedule that does not alter,
which aims to avoid UI by providing fixed opportunities for
bladder emptying prior to exceeding bladder capacity.
• Habit training: a voiding schedule that matches the
patterns of the individual but pre-empts episodes of
incontinence, therefore, variability in the regimen may be
evident throughout the day (Dumoulin 2017).
Bowel management regimens focus on keeping the rectum empty
and the avoidance of constipation and diarrhoea through the es-
tablishment of a regular, predictable pattern of bowel evacuation.
Loose stools and constipation are risk factors for faecal inconti-
nence and the main conservative strategies to avoid these are de-
tailed below.
• Bowel habit and toileting: establishing a pattern for bowel
evacuation is promoted, with the period following breakfast
being encouraged when peristaltic contractions of the colon are
increased.
• Urgency resistance training: teaching strategies to resist the
urge to defecate.
• Evacuation training: education and advice to avoid
straining and promote appropriate toilet positioning in order to
achieve positive evacuation habits.
• Digital stimulation and manual evacuation: strategies to
facilitate emptying of the bowel to facilitate a bowel evacuation
pattern (Bliss 2017).
Rectal irrigation
Rectal irrigation is the process of water being passed into the anus
to reach beyond the rectum to stimulate colonic reflex activity and
mechanically wash out the bowel (Coggrave 2014). This method
of management enables the timing of bowel opening to be con-
trolled and scheduled for convenience, thereby reducing the risk
of an unpredictable occurrence of faecal incontinence.
Intermittent catheter use
Urinary catheters provide a physical method for removing urine
from the bladder as a strategy to reduce incontinence. Intermit-
tent catheters can be passed into the bladder via the urethra at a
convenient time and are immediately removed. They provide a
method for removing urine that is controlled, and to reduce the
amount of urine in the bladder that may otherwise leak. Catheters
must always be carefully considered due to their associated risks
of infection (Cottenden 2017).
Why it is important to do this review
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Incontinence symptoms are amenable to conservative treatment
interventions in other disease states and a limited number of trials
have indicated benefits for individuals with MS. However, there
has not been a comparison of the studies to assimilate what can be
concluded about its effect in this population. In addition, studies
have focused on certain aspects of incontinence or certain sections
of the population so it is unclear if there are consensus findings
that can be used to inform practice. The economic impact of in-
continence - in terms of financial burden to the individuals with
MS due to resource use and loss of earnings, and for the healthcare
provider - are unknown. Our review is one of several Cochrane
Reviews which address conservative management of these symp-
toms and the associated costs, which include the following.
• Pelvic floor muscle training added to another active
treatment versus the same active treatment alone for urinary
incontinence in women (Ayeleke 2015)
• Lifestyle interventions for the treatment of urinary
incontinence in adults (Imamura 2015)
• Pelvic floor muscle training versus no treatment, or inactive
control treatments, for urinary incontinence in women
(Dumoulin 2014)
• Management of faecal incontinence and constipation in
adults with central neurological diseases (Coggrave 2014)
• Weighted vaginal cones for urinary incontinence (Herbison
2013)
• Biofeedback and/or sphincter exercises for the treatment of
faecal incontinence in adults (Norton 2012)
• Combined conservative interventions for urge, stress or
mixed incontinence in adults (French 2010)
O B J E C T I V E S
To assess the effects of conservative interventions for urinary or
faecal incontinence (or both) in adults with multiple sclerosis,
compared to no treatment, sham and usual care, any other active
treatment, or another conservative treatment.
To critically appraise and summarise the current evidence on re-
source use, costs and cost effectiveness of conservative interven-
tions for adults with urinary or faecal incontinence (or both) and
MS.
We will make the following comparisons.
• Conservative treatment versus no treatment
• Conservative treatment versus sham treatment
• Conservative treatment versus usual care
• Conservative treatment versus pharmacological treatment
• Conservative treatment versus surgical treatment
• Conservative treatment versus any other conservative
treatment
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider parallel group randomised controlled trials
(RCTs) and quasi-randomised studies. We will also include the
first phase of crossover RCTs (to avoid carry over effects from the
initial intervention phase). We will also search for economic eval-
uations of the different interventions.
Types of participants
All male and female adults aged over 18 years with existing uri-
nary, faecal or anal incontinence (or a combination of these), with
a clinical diagnosis of relapsing/remitting, primary or secondary
progressive multiple sclerosis (MS). Incontinence will be estab-
lished on the basis of symptoms, signs or urodynamic or anorectal
physiology studies.
Types of interventions
One arm of all eligible trials must use a conservative intervention
to treat urinary or faecal incontinence, or both, which includes:
• pelvic floor muscle training programme (PFMT);
• weighted vaginal cones;
• electrical stimulation;
• posterior tibial nerve stimulation (PTNS);
• magnetic stimulation;
• biofeedback;
• lifestyle interventions such as diet and behaviour choices;
• scheduled voiding and bowel management regimens;
• rectal irrigation;
• intermittent catheter use.
It is recognised that there will not be standardisation between the
treatment protocols and therefore variability between programmes
will be accepted. We will exclude studies of conservative strategies
for prevention of incontinence.
Comparator arms will include no treatment, usual care, sham,
pharmacological and surgical interventions, and any of the above
interventions.
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Types of outcome measures
Primary outcomes
• Number of participants with self-reported ‘improved’
urinary incontinence (UI) according to validated symptom score,
for example, ICIQ-UI Short Form (Avery 2004), Incontinence
Severity Index (Sandvik 1993)
• Number of participants with self-reported ‘improved’ faecal
incontinence (FI) according to validated symptom score, for
example ICIQ-B (Cotterill 2008), FISI (Rockwood 1999),
BBUSQ (Hiller 2002)
• Validated quality-of-life scores, for example, ICIQ-
LUTSqol (Abrams 2006; Kelleher 1997), ICIQ-UI Short Form
‘Overall bother’ item (Avery 2004), ICIQ-B ‘Quality of life’
domain (Cotterill 2008), FIQL (Rockwood 2000)
Secondary outcomes
Participant observations
• Degree of improvement in incontinence symptoms
(validated scores, as measured for primary outcomes)
• Number of participants with alleviation of other urinary or
bowel symptoms (validated scores, as measured for primary
outcomes)
• Number of participants with improvement in sexual
function (validated sexual function self-report measures)
• Satisfaction with treatment
• Compliance with treatment
Quantification of symptoms
• Frequency of incontinence episodes (bladder/bowel diaries)
• Pad tests (weight)
• Number of pad changes (diaries)
Clinician’s observations
• We will not include clinician observations, in order to retain
a focus on subjective outcomes rather than clinical parameters
Adverse effects
• Number of adverse events reported in the trials
• Number of participants with worsening of other urinary or
bowel symptoms (validated scores as measured for primary
outcomes)
• Number of participants with deterioration in sexual
function (validated sexual function measures)
Economic outcomes
• Resource (type and number) used to deliver the
conservative management treatment
• Cost of the intervention to health service provider, such as
cost of staff, cost of treatment and care
• Costs of the resources for the patient, such as conservative
management equipment, lost wages and lost productivity
• Cost effectiveness (incremental cost effectiveness ratios
(ICERs), increment cost per quality adjusted life years (QALYs),
incremental cost per disability adjusted life year (DALY),
incremental cost benefit ratios, net benefit)
Other outcomes
• Unspecified outcomes judged to be important by the review
authors when performing the review
Timing of outcome measures
We will divide outcome time points into short-term (up to three
months),medium-term (between three and sixmonths), and long-
term (greater than six months), from the start of the intervention.
Search methods for identification of studies
Electronic searches
The InformationSpecialist will search theCochraneMultiple Scle-
rosis and Rare Diseases of the Central Nervous SystemGroup Tri-
als Register which, among other sources, contains trials from the
following.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (latest issue)
• MEDLINE (PubMed) (1966 to date)
• Embase (1974 to date)
• CINAHL (EBSCO host) (1981 to date)
• LILACS (Bireme) (1982 to date)
• PEDro (1990 to date)
• ClinicalTrials.gov (www.clinicaltrials.gov)
• World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( apps.who.int/trialsearch)
Information on the Group’s Trials Register and details of search
strategies used to identify trials can be found in the ’Specialised
Register’ section within the Cochrane Multiple Sclerosis and Rare
Diseases of the Central Nervous System Group’s module. The
keywords used to search for trials for this review are listed in
Appendix 1.
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Searching other resources
We will search for conference proceedings to identify studies po-
tentially missed through the database searches and articles from
‘grey literature’. This will include the following since 2002.
• We will check the reference lists from published reviews to
identified RCTs.
• We will check for conference proceedings for the annual
meetings of the United Kingdom Continence Society, European
Committee for Treatment and Research in Multiple Sclerosis,
Americas Committee for Treatment and Research in Multiple
Sclerosis and European Multiple Sclerosis Platform.
• We will check for reviews from the International
Consultation on Incontinence 2016 (Abrams 2017).
• We will contact authors and trialists of included studies.
Data collection and analysis
Selection of studies
Wewill enter all trials identified from the search into ReviewMan-
ager 5 software ( RevMan 2014). Two review authors (NC and
AS) will evaluate all studies’ titles and abstracts according to the
inclusion criteria. We will then access full papers of potentially
relevant studies for further assessment of eligibility. Any discrep-
ancies at either stage of screening will be resolved by discussion,
and where disagreements remain unresolved a third author (MD)
will make the final decision. All excluded studies will be listed with
reasons for exclusion.
Data extraction and management
Two review authors (NC and AS) will independently extract data
using a data extraction form, and they will cross-reference the
information. Extracted data will include:
• date and location of study;
• study design, including methodological quality;
• characteristics of participants (number, setting, age, type of
MS, nature of UI/FI diagnosis);
• inclusion and exclusion criteria;
• details of the experimental intervention, including duration;
• details of the comparator arm;
• description of outcomes.
Any discrepancies will be resolved by discussion and, if required, a
third review author (MD). Where study data are unclear or not re-
ported in a form thatmay be useful for formal comparison, further
clarification will be sought from the trial authors. We will process
all included trial data as described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Assessment of risk of bias in included studies
Two review authors (NC and AS) will undertake critical appraisal
of the included studies usingCochrane’s ’Risk of bias’ tool (Higgins
2011) to assess the risk of bias. It is recognised that given the nature
of the interventions, allocation blinding may be difficult, but areas
of evaluation will include the following.
• Was there adequate random sequence generation for
treatment allocation (selection bias)?
• Was there adequate concealment of allocation to
intervention arm prior to allocation (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study (performance bias)?Were
• Were outcome assessors blinded (detection bias)?
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Was the study free of the suggestion of selective reporting
(reporting bias)?
• Was the study free of other issues that could put it as risk of
bias?
For each domain we will categorise each study as being at low/
unclear or high risk of bias (Higgins 2011). Any discrepancies will
be resolved by discussion and, if required, by involving a third
review author (MD). The global risk of bias for all the included
studies will be displayed in a ’Risk of bias’ graph to aid clarity for
each included study. We will also summarise the risk of bias across
domains to provide an overview of strengths and limitations in the
body of research.
Measures of treatment effect
We will use risk ratios (RRs) with 95% confidence intervals (CIs)
to express the effect size for categorical data. We will use means
and standard deviations to derive mean differences (MDs) with
95% CIs for continuous variables. We plan to undertake meta-
analysis where appropriate.
Unit of analysis issues
Trials containing two active treatment comparisons in combina-
tion will be included where identified (e.g. bladder training +
PFMT versus both a bladder training arm and a PFMT arm).
Where combined active treatments are compared with each treat-
ment individually (e.g. bladder training + PFMT versus bladder
training only versus PFMT only), we will choose one comparison
arm to include in the review to avoid double counting the inter-
vention arm. The comparator anticipated to be least effective to
the combined intervention will be selected initially, to identify a
treatment effect of any magnitude. We will then undertake a post-
hoc sensitivity analysis, replacing the chosen comparator (antici-
pated to be least effective) with the alternative comparator (antici-
pated to be most effective). This is proposed to avoid over-estima-
tion in the estimation of treatment effect but to provide outcome
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data for each treatment intervention. We will include cross-over
trials, but only the first phase will be used to avoid problems with
carry-over effects.
Dealing with missing data
If required, we will request further information from the origi-
nal trial author by written correspondence (e.g. emailing corre-
sponding author/s), and we will include any relevant information
obtained in this manner in the review. All missing data will be
assumed ‘missing at random’ but only observed data will be in-
cluded, without imputation.
Assessment of heterogeneity
Wewill examine clinical heterogeneity between the trials consider-
ing the similarities between the characteristics of the populations,
types of interventions and outcomes. We will explore statistical
heterogeneity using the I2 statistic and by visual inspection of the
forest plots, according to the methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will define an I2 of more than 50% as representing substantial
heterogeneity, beneath which a fixed-effect model will be used for
meta-analysis. Where there is substantial heterogeneity, wewill use
both fixed- and random-effects models, and will report the most
conservative method if the results differ. If it is considered inap-
propriate to combine data from the included studies, we intend
to present a narrative synthesis of the results.
Assessment of reporting biases
To estimate the influence of unpublished studies on the overall
effects, wewill produce a funnel plot if there are ten ormore studies
included in the analysis.
Data synthesis
We will synthesise data according to the outcomes through meta-
analysis, narrative/descriptive analysis, or both, depending on the
availability and appropriateness of data from the included studies,
using the fixed-effect model if appropriate. We will analyse the
data using Review Manager 2014.
Subgroup analysis and investigation of heterogeneity
If sufficient data are available, we will analyse treatment effects in
the following subgroups:
• participant gender;
• type and duration of incontinence (stress urinary
incontinence, urgency urinary incontinence, mixed urinary
incontinence, faecal incontinence, mixed urinary and anal or
faecal incontinence);
• MS diagnosis and duration (relapsing remitting, primary
progressive, secondary progressive).
Sensitivity analysis
Wewill perform sensitivity analysis to evaluate themethodological
quality of trials by including or excluding studies with moderate
or high risk of bias. Overall risk of bias will be judged based on
domain-level judgements with ‘low risk’ of overall bias indicated
where a study is judged to be at low risk of bias for all domains,
‘some concerns’ indicated where a study has evidence of some
concerns in at least one domain, and ‘high risk’ where a study is
at high risk in one domain or displays evidence of some concerns
across multiple domains, as described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
’Summary of findings’ table
We will use the GRADE approach to evaluate the quality of the
body of evidence collected (GRADEWorking Group 2004). Two
review authors (NS and AS) will rate the quality of evidence for
each outcome, from ’high’, which indicates that further research
is unlikely to alter the estimate of effect, through to ’very low’,
where an estimate of effect is very uncertain. Any discrepancies
will be resolved by consensus and a third review author (MD).
We will produce ‘Summary of findings’ tables, which will include
detail regarding the quality of the evidence, magnitude of treat-
ment effect and summary of the main outcomes according to the
published criteria. Gradings will be reduced to reflect the influ-
ence of study limitations and inconsistencies. Additional outcomes
regarding degree of improvement, alleviation or exacerbation of
other symptoms and economic outcomes will be presented. We
will produce separate ’Summary of findings’ tables for UI and FI,
and will include the following outcomes across all time points
(short-, medium- and long-term).
• Number of participants with self-reported ‘improved’
urinary incontinence
• Number of participants with self-reported ‘improved’ faecal
incontinence
• Quality-of-life scores
• Magnitude of improvement
• Degree of improvement in incontinence symptoms
(validated scores as measured for primary outcomes)
• Number of participants with alleviation of other urinary or
bowel symptoms (validated scores as measured for primary
outcomes)
• Number of participants with worsening of other urinary or
bowel symptoms (validated scores as measured for primary
outcomes)
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A P P E N D I C E S
Appendix 1. Detailed search strategy
(((((((((“Urinary Incontinence”[Mesh]) OR “Fecal Incontinence”[Mesh])) OR (“urinary incontinence”[Title/Abstract]) OR “faecal
incontinence”[Title/Abstract])) OR ((“involuntary leakage” OR “involuntary loss” OR “involuntary loss of faecal” OR “flatus incon-
tinence” OR “involuntary flatus” OR “involuntary loss of gas” OR “lower urinary tract dysfunction” OR “lower bowel tract dysfunc-
tion”))))) OR (“urinary incontinence”[Title/Abstract] OR “faecal incontinence”[Title/Abstract])))
AND
((((((((((“Multiple Sclerosis”[Mesh:noexp] OR “Multiple Sclerosis, Chronic Progressive”[Mesh]) OR “Multiple Sclerosis, Relaps-
ing-Remitting”[Mesh]) OR “Demyelinating Diseases”[Mesh:noexp]) OR “Optic Neuritis”[Mesh]) OR “Demyelinating Autoim-
mune Diseases, CNS”[Mesh:noexp]) OR “Encephalomyelitis, Acute Disseminated”[Mesh]) OR “Myelitis, Transverse”[Mesh]) OR
(((((((((((((((((“multiple sclerosis”[Title/Abstract]) OR “chronic progressive multiple sclerosis”[Title/Abstract]) OR “progressive relaps-
ing multiple sclerosis”[Title/Abstract]) OR “secondary progressive multiple sclerosis”[Title/Abstract]) OR “primary progressive mul-
tiple sclerosis”[Title/Abstract]) OR “relapsing remitting multiple sclerosis”[Title/Abstract]) OR “remitting-relapsing multiple sclero-
sis”[Title/Abstract]) OR “acute relapsingmultiple sclerosis”[Title/Abstract]) OR “neuromyelitis optica”[Title/Abstract]) OR “optic neu-
ritis”[Title/Abstract]) OR “devic disease”[Title/Abstract]) OR “demyelinating disease”[Title/Abstract]) OR adem[Title/Abstract]) OR
“demyelinating disorder”[Title/Abstract]) OR “clinically isolated syndrome”[Title/Abstract]) OR “transverse myelitis”[Title/Abstract])
OR “acute disseminated encephalomyelitis”[Title/Abstract] OR (“encephalomyelitis”[Title/Abstract])))))))
AND
(((((((“Electric Stimulation Therapy”[Mesh]) OR “Magnetic Field Therapy”[Mesh:NoExp]))) OR “Urinary Catheters”[Mesh]) OR
(“pelvic floor muscle training” OR “weighted vaginal cones” OR “electrical stimulation” OR “magnetic stimulation” OR “biofeedback”
OR “rectal irrigation” OR “sacral neuromodulation” OR “urinary catheters” OR “intermittent catheters”)) OR (“scheduled voiding”
OR “timed voiding” OR “prompted voiding” OR “bowel management regimens”)) OR (“lifestyle” OR “lifestyle modification” OR
“weight reduction” OR “physical activity” OR “exercise” OR “smoking cessation” OR “smoking reduction” OR “diet” OR “caffeine”
OR “fluid manipulation” OR “constipation” OR “stress reduction”))
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